4808 Results

People

  1. Travis
    Travis
  2. Berger
    Berger
  3. Hudis
    Hudis
  4. Ladanyi
    Ladanyi
  5. Arcila
    Arcila
  6. Reis-Filho
    Reis-Filho
  7. Weigelt
    Weigelt
  8. Giralt
    Giralt
  9. Levine
    Levine
  10. Motzer
    Motzer

Groups

  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)
  7. Department of Pathology and Laboratory Medicine (714)
  8. Hematologic Malignancies, Division of (683)
  9. Population Sciences Research Program (601)
  10. Sloan Kettering Institute Faculty (586)
  1. "2015"
Formats
  1. Journal Article (2716)
  2. Meeting Abstract (1680)
  3. Book Section (364)
  4. Conference Paper (26)
  5. Book Whole (19)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (1855)
  2. GSK Faculty (1116)
  3. Solid Tumor Oncology Division (1035)
  4. Surgery (883)
  5. Survivorship Research (752)
  6. Center for Hematologic Malignancies (746)

More Groups

People
  1. William Travis (102)
  2. Michael Berger (96)
  3. Clifford Hudis (85)
  4. Marc Ladanyi (79)
  5. Jedd Wolchok (68)
  6. Britta Weigelt (67)

More People

Years
  1. 2015 (4808)
Publications
  1. Journal of Clinical Oncology (475)
  2. Blood (224)
  3. Cancer Research (168)
  4. Modern Pathology (125)
  5. Laboratory Investigation (112)
  6. International Journal of Radiation Oncology, Biology, Physics (91)

More Publications

Publishers
  1. Elsevier Inc. (581)
  2. American Society of Clinical Oncology (508)
  3. Springer (380)
  4. Nature Publishing Group (301)
  5. American Association for Cancer Research (263)
  6. American Society of Hematology (228)

More Publishers

Results (4808)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001
    Meeting Abstract

    Robert, C.; Joshua, A. M.; Kefford, R.; Joseph, R. W.; Wolchok, J. D.; Hodi, F. S.; Hamid, O.; Weber, J. S.; Gangadhar, T. C.; Dronca, R. S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001
    Meeting Abstract

    Rizvi, N. A.; Garon, E. B.; Leighl, N.; Hellmann, M. D.; Patnaik, A.; Gandhi, L.; Eder, J. P.; Rangwala, R. A.; Lubiniecki, G.; Zhang, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Rizvi, N. A.; Brahmer, J. R.; Ou, S. H. I.; Segal, N. H.; Khleif, S.; Hwu, W. J.; Gutierrez, M.; Schöffski, P.; Hamid, O.; Weiss, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers
    Meeting Abstract

    Riely, G. J.; Yu, H. A.; Stephens, D.; Pietanza, M. C.; Smith-Marrone, S.; Fiore, J. J.; Goldstein, M.; Sima, C. S.; Kris, M. G.; Ginsberg, M. S.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • FDG-PET/CT versus contrast enhanced CT for prediction of progression-free and disease-specific survival in stage IV breast cancer patients
    Meeting Abstract

    Riedl, C.; Pinker, K.; Ong, L.; Jochelson, M. S.; Ulaner, G.; Mcarthur, H. L.; Dickler, M. N.; Weber, W.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma
    Meeting Abstract

    Ribas, A.; Butler, M.; Lutzky, J.; Lawrence, D. P.; Robert, C.; Miller, W.; Linette, G. P.; Ascierto, P. A.; Kuzel, T.; Algazi, A. P.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature
    Meeting Abstract

    Ribas, A.; Robert, C.; Hodi, F. S.; Wolchok, J. D.; Joshua, A. M.; Hwu, W. J.; Weber, J. S.; Zarour, H. M.; Kefford, R.; Loboda, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM)
    Meeting Abstract

    Reardon, D. A.; Dietrich, J.; Kaley, T. J.; Gan, H. K.; Dunn, G. P.; Cloughesy, T. F.; Lim, M.; Clarke, J. L.; Park, A. J.; Pan, L. S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis
    Meeting Abstract

    Raut, C. P.; Espat, N. J.; Maki, R. G.; Araujo, D. M.; Keir, C. H.; Williams, T. F.; DeMatteo, R. P.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Attard, G.; Efstathiou, E.; Yu, M. K.; Griffin, T. W.; Todd, M. B.; Wu, D.; Kheoh, T.; Zhao, X.; Saad, F.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save